Skip to content

Study on Accurate Diagnosis of Non-alcoholic Fatty Liver Disease by Multimodal Ultrasound

Study on Accurate Diagnosis of Non-alcoholic Fatty Liver Disease by Multimodal Ultrasound

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038301
Enrollment
Unknown
Registered
2020-09-17
Start date
2020-09-21
Completion date
Unknown
Last updated
2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease

Interventions

Gold Standard:Pathological diagnosis
Index test:Diagnostic&#32
model&#32
for&#32
with&#32
ultrasound&#32
technology

Sponsors

China–Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: For the adult patients with metabolic syndrome who plan to undergo weight loss surgery in the weight loss center of our hospital, the patients have the following weight loss surgery indications: 1. In patients with type 2 diabetes = 1/2 of the lower limit of normal value; 2. Patients with BMI >= 27.5; 3. When waist circumference >= 90cm for men and >= 85cm for women, the recommended level of surgery can be improved as appropriate. 4. Patients aged 18-65 years are recommended; 5. The above standard, by the weight loss center doctors to assess patients with metabolic syndrome and other complications, including type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea and obesity hypoventilation syndrome, alcoholic fatty liver disease and nonalcoholic fatty hepatitis, gastroesophageal reflux disease, bronchus asthma, serious incontinence, arthritis, or seriously affect the quality of life.

Exclusion criteria

Exclusion criteria: Combined with other causes of liver disease, 1. In patients with alcoholic liver disease, the amount of alcohol consumed was 140 g > per week for men and 70g b > per week for women. 2. Patients with specific diseases that can lead to fatty liver, such as viral hepatitis, drug-induced liver disease, total parenteral nutrition, hepatolenticular degeneration, autoimmune liver disease, etc.

Design outcomes

Primary

MeasureTime frame
SWE;liver fibrosis index;attenuation test (ATT);SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactBo Zhang

China–Japan Friendship Hospital

779053916@qq.com+86 10-84205417

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026